Atlantic Health System and Atlantic Center for Research Deliver New Chapter in Bladder Cancer Care
Dr. Sandip Prasad leads an international trial that brings new bladder-sparing therapy to patients
-
1
Dr. Sandip Prasad led the ENVISION phase 3 trial, introducing the FDA-approved bladder-sparing therapy Zusduri™ for NMIBC patients.
-
2
Zusduri™ is a reverse thermal gel that delivers mitomycin directly into the bladder, providing a non-surgical treatment option.
-
3
Atlantic Health System was a top-enrolling site for the ENVISION trial, showcasing collaboration between clinical and research teams.
-
4
The approval of Zusduri™ represents a significant advancement in bladder cancer care, offering patients a choice beyond surgery.
-
5
Atlantic Health System aims to enhance cancer treatment through innovative research, improving patient outcomes and quality of life.
